NasdaqGM - Nasdaq Real Time Price USD

TransMedics Group, Inc. (TMDX)

Compare
144.56 -3.72 (-2.51%)
At close: September 26 at 4:00 PM EDT
156.55 +11.99 (+8.29%)
Pre-Market: 6:45 AM EDT
Loading Chart for TMDX
DELL
  • Previous Close 148.28
  • Open 150.10
  • Bid 144.49 x 100
  • Ask 144.75 x 200
  • Day's Range 141.40 - 150.30
  • 52 Week Range 36.42 - 177.37
  • Volume 838,375
  • Avg. Volume 819,347
  • Market Cap (intraday) 4.816B
  • Beta (5Y Monthly) 1.99
  • PE Ratio (TTM) 3,614.00
  • EPS (TTM) 0.04
  • Earnings Date Nov 4, 2024 - Nov 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 183.00

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

www.transmedics.com

584

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMDX

View More

Performance Overview: TMDX

Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMDX
83.15%
S&P 500
20.45%

1-Year Return

TMDX
170.36%
S&P 500
32.46%

3-Year Return

TMDX
360.82%
S&P 500
28.95%

5-Year Return

TMDX
523.10%
S&P 500
92.48%

Compare To: TMDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMDX

View More

Valuation Measures

Annual
As of 9/26/2024
  • Market Cap

    4.82B

  • Enterprise Value

    4.97B

  • Trailing P/E

    3.62k

  • Forward P/E

    105.26

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    13.64

  • Price/Book (mrq)

    25.39

  • Enterprise Value/Revenue

    13.87

  • Enterprise Value/EBITDA

    164.21

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.84%

  • Return on Assets (ttm)

    2.45%

  • Return on Equity (ttm)

    1.79%

  • Revenue (ttm)

    358.76M

  • Net Income Avi to Common (ttm)

    3M

  • Diluted EPS (ttm)

    0.04

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    362.75M

  • Total Debt/Equity (mrq)

    271.99%

  • Levered Free Cash Flow (ttm)

    -240.13M

Research Analysis: TMDX

View More

Company Insights: TMDX

Research Reports: TMDX

View More

People Also Watch